Post Profile






Ticagrelor after MI: Added benefit called into question by data subsequently submitted

(Institute for Quality and Efficiency in Health Care) New analyses increased consistency and certainty of conclusions of the results on harmful aspects. Non-severe but clinically relevant bleeding also occurred more frequently under ticagrelor.
read more

share

Related Posts


First feasibility study of the ESMO-MCBS scale in rare tumor entities

Health : EurekAlert: Health

(European Society for Medical Oncology) The results of the first study analysing the application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) in a real-life context for rare tumour entities, were announced today at th...

Disease management programme for asthma is largely consistent with guidelines

Health : Medical News Today

Current guidelines are more detailed regarding some aspects of treatmentOn 22 January 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinic...

DMP is largely consistent with COPD guidelines

Health : Medical News Today

Current guidelines are more detailed regarding some aspects of treatmentThe German Institute for Quality and Efficiency in Health Care (IQWiG) has published the results of a literature search for evidence-based clinical practice gui...

Ibrutinib in CLL: Added benefit for treatment-naive patients not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The dossier contained no suitable data for any of the three subgroups of treatment-naive patients with chronic lymphocytic leukaemia, for whom the drug was newly approved in 2016...

Saxagliptin and saxagliptin/metformin in type 2 diabetes: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The presented analyses of the SAVOR-TIMI 53 study were unsuitable for conclusions on positive or negative effects in comparison with the appropriate comparator therapies.

Comments


Copyright © 2016 Regator, LLC